Petros Pharmaceuticals, Inc.
PTPI
$0.0919
-$0.0106-10.34%
| Weiss Ratings | PTPI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | PTPI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | PTPI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.62 | |||
| Price History | PTPI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -7.92% | |||
| 30-Day Total Return | -68.32% | |||
| 60-Day Total Return | -73.98% | |||
| 90-Day Total Return | -75.83% | |||
| Year to Date Total Return | -80.34% | |||
| 1-Year Total Return | -93.83% | |||
| 2-Year Total Return | -94.33% | |||
| 3-Year Total Return | -99.16% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -93.86% | |||
| 52-Week Low % Change | 40.22% | |||
| Price | PTPI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.67 | |||
| 52-Week Low Price | $0.07 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Mar 19, 2024 | |||
| Valuation | PTPI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.03M | |||
| Enterprise Value | 4.47M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -4.69 | |||
| Earnings Per Share Growth | -30.50% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.25 | |||
| Price/Book (Q) | 0.33 | |||
| Enterprise Value/Revenue (TTM) | 1.11 | |||
| Price | $0.09 | |||
| Enterprise Value/EBITDA (TTM) | -0.42 | |||
| Enterprise Value/EBIT | -0.33 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | PTPI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 9.83M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | PTPI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 973 242 0005 | |||
| Address | 1185 Avenue of the Americas New York, NY 10036 | |||
| Website | www.petrospharma.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | PTPI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -337.79% | |||
| Profit Margin | -117.52% | |||
| Management Effectiveness | PTPI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -28.49% | |||
| Return on Equity | -- | |||
| Income Statement | PTPI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 4.02M | |||
| Total Revenue (TTM) | 4.02M | |||
| Revenue Per Share | $0.41 | |||
| Gross Profit (TTM) | 2.92M | |||
| EBITDA (TTM) | -10.61M | |||
| EBIT (TTM) | -13.59M | |||
| Net Income (TTM) | -4.73M | |||
| Net Income Avl. to Common (TTM) | -4.73M | |||
| Total Revenue Growth (Q YOY) | -5.87% | |||
| Earnings Growth (Q YOY) | 51.19% | |||
| EPS Diluted (TTM) | -4.69 | |||
| EPS Diluted Growth (Q YOY) | 81.28% | |||
| Balance Sheet | PTPI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 3.89M | |||
| Cash Per Share (Q) | $0.40 | |||
| Total Current Assets (Q) | 10.72M | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | 3.12M | |||
| Current Ratio (Q) | 0.854 | |||
| Book Value Per Share (Q) | $0.31 | |||
| Total Assets (Q) | 20.69M | |||
| Total Current Liabilities (Q) | 12.56M | |||
| Total Debt (Q) | 7.34M | |||
| Total Liabilities (Q) | 17.58M | |||
| Total Common Equity (Q) | 3.12M | |||
| Cash Flow | PTPI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -19.10K | |||
| Cash from Financing (TTM) | -8.23M | |||
| Net Change in Cash (TTM) | -14.08M | |||
| Levered Free Cash Flow (TTM) | -2.03M | |||
| Cash from Operations (TTM) | -5.83M | |||
